Office for Technology Commercialization

Bioresorbable Occlusion Device for Congenital Heart Defects

Technology #z02056

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Bioresorbable Occlusion Device Congenital Cardiovascular Defect Atrial Septal Defect
Gladwin Das, MD.
Associate Professor, Cardiovascular Division, Department of Medicine
External Link (
Managed By
Kevin Anderson
Technology Licensing Officer 612-624-8293
Patent Protection

US Patent pending

US Patent Pending

Self-Centering, Bioresorbable, Occlusion Device

This medical device can close congenital heart defects and is self-centering, can completely occlude defects, and be retrieved back to the catheter in the event of sub-optimal deployment. The device is designed to be bioresorbable and has no metallic components. This simplifies the manufacturing of the device and allows the device to degrade over time and be replaced by natural fibrous tissue in the body. This is the ideal solution for congenital heart defects; a temporary device that is resorbed by the body and replaced with native tissue.

MN-IP Try and Buy
This technology is available via a standard negotiated license agreement. Contact Kevin Anderson for specific details.

Congenital Heart Defects and Current Treatment Challenges

Congenital heart defects are the most common type of birth defect. They affect eight out of every 1,000 newborns. Each year, more than 35,000 babies in the United States are born with congenital heart defects. A septal defect, or “hole in the heart” can occur between the atria or the ventricles. Patent ductus arteriosus (PDA) is a fairly common heart defect that can occur soon after birth. In PDA, abnormal blood flow occurs between the aorta and the pulmonary artery. With advances in diagnostic and catheter methods, it has become possible to close these defects with minimally invasive medical devices.

Non-metallic Occlusion Device

Current closure devices generally contain metallic features to provide shape support. These can erode into surrounding tissue and corrode over the 70 year potential lifetime of the device. Newer devices include self-centering features to reduce the potential for residual leaks and provide complete occlusion of the defect. However due to the presence of metallic wires these devices are bulky and can cause unintended flow disruptions. A solution for this problem is the bioresorbable non-metallic closure device that can self-center, completely occlude defects, and be retrieved back to the catheter in the event of sub-optimal deployment.


  • Designed to work with all types of heart defects in the cardiovascular system such as atrial septal defects, ventricular septal defects, patent ductus arteriosus and patent foramen ovale in addition to closing arterial puncture sites, reducing hospital inventory and simplifying the implant procedure.
  • Bioresorbable elements are eventually replaced by native tissues, leading to a more physiologic solution and minimizing long term adverse events.
  • Completely self-centering, to help blood shunting around the device.